One Year Later: The FDA Safety and Innovation Act
We're pleased to share with you a guest post from Cynthia Bens, vice president, public policy, Alliance for Aging Research.
It’s been a little over a year since President Obama signed the Food and Drug Administration Safety and Innovation Act (FDASIA) into law. This legislation uses increased industry user fees and a series of additional reforms aimed at relieving the agency’s backlogs of drug and medical technology approvals and speeding the flow of new health care innovations to patients.
We're pleased to share with you a guest post from Cynthia Bens, vice president, public policy, Alliance for Aging Research.
It’s been a little over a year since President Obama signed the Food and Drug Administration Safety and Innovation Act (FDASIA) into law. This legislation uses increased industry user fees and a series of additional reforms aimed at relieving the agency’s backlogs of drug and medical technology approvals and speeding the flow of new health care innovations to patients.
To better understand how the reality of FDASIA is matching the law’s promise – particularly its effect on diseases affecting America’s seniors – the Alliance for Aging Research is hosting a roundtable discussion on Tuesday, September 17. “One Year Later: The Food and Drug Administration Safety and Innovation Act” will take place at the Willard Intercontinental Hotel from 5 p.m. to 6:30 p.m.
The discussion will include high-ranking FDA officials including Janet Woodcock, M.D. and Jeff Shuren, M.D., J.D., the directors, respectively, of the Center for Drug Evaluation and Research and the Center for Devices and Radiological Health. For more information and to register for the event, click here.
The opinions expressed here are the author's views.